Thromb Haemost
DOI: 10.1055/a-1366-9656
Original Article

Prevalence and Predictors of Venous Thromboembolism or Mortality in Hospitalized COVID-19 Patients

VTE in Hospitalized COVID-19 Patients
1  Northwell Health, great neck, United States (Ringgold ID: RIN5799)
,
Eugenia Gianos
2  Northwell Health, radiology, great neck, United States (Ringgold ID: RIN5799)
,
Matthew A Barish
2  Northwell Health, radiology, great neck, United States (Ringgold ID: RIN5799)
,
Saurav Chatterjee
2  Northwell Health, radiology, great neck, United States (Ringgold ID: RIN5799)
,
Nina Kohn
2  Northwell Health, radiology, great neck, United States (Ringgold ID: RIN5799)
,
Martin Lesser
2  Northwell Health, radiology, great neck, United States (Ringgold ID: RIN5799)
,
Dimitrios Giannis
2  Northwell Health, radiology, great neck, United States (Ringgold ID: RIN5799)
,
Kevin Coppa
2  Northwell Health, radiology, great neck, United States (Ringgold ID: RIN5799)
,
Jamie Hirsch
2  Northwell Health, radiology, great neck, United States (Ringgold ID: RIN5799)
,
Thomas McGinn
2  Northwell Health, radiology, great neck, United States (Ringgold ID: RIN5799)
,
Mark Goldin
2  Northwell Health, radiology, great neck, United States (Ringgold ID: RIN5799)
,
Alex Spyropoulos
3  Hofstra, Northwell School of Medicine, Department of Medicine, Northwell Health at Lenox Hill Hospital, NY, United States
› Author Affiliations




Objectives: To identify the prevalence and predictors of VTE or mortality in hospitalized COVID-19 patients. Methods: A retrospective cohort study of adult COVID-19 patients admitted to an integrated health care network in the New York metropolitan region between March 1, 2020 and April 27, 2020. The final analysis included 9407 patients with an overall VTE rate of 2.9% (2.4% in the medical ward and 4.9% in the ICU) and a VTE or mortality rate of 26.1%. Most patients received prophylactic-dose thromboprophylaxis. Multivariable analysis showed significantly reduced VTE or mortality with Black race, history of hypertension, angiotensin converting enzyme/angiotensin receptor blockers use, and initial prophylactic anticoagulation. It also showed significantly increased VTE or mortality with age 60 years or greater, Charlson Comorbidity Index (CCI) of 3 or greater, patients on Medicare, history of heart failure, history of cerebrovascular disease, body mass index greater than 35, steroid use, anti-rheumatologic medication use, hydroxychloroquine use, maximum D-dimer 4 times or greater than the upper limit of normal (ULN), ICU level of care, increasing creatinine, and decreasing platelet counts. Conclusion: In our large cohort of hospitalized COVID-19 patients, the overall in-hospital VTE rate was 2.9% (4.9% in the ICU) and a VTE or mortality rate of 26.1%. Key predictors of VTE or mortality included advanced age, increasing CCI, history of cardiovascular disease, ICU level of care, and elevated maximum D-dimer with a cutoff at least 4 times the ULN. Use of prophylactic-dose anticoagulation but not treatment-dose anticoagulation was associated with reduced VTE or mortality.



Publication History

Received: 30 November 2020

Accepted after revision: 18 January 2021

Publication Date:
20 January 2021 (online)

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany